Clinical Cardiology Resource Center Editorial Programs

 
 
  • Can 'Normal' T4 Levels Increase AF Risk?   To minimize AF risk, should T4 levels be monitored in patients being treated for hypothyroidism?
  • SGLT2 Inhibitors: Is This the Start of a New Era? Gregory Nichols discusses exciting new clinical trial results demonstrating the benefits of SGLT2 inhibitors, as presented at the AHA 2018 Scientific Sessions.
  • Analyze This Image: Remote History of Mitral Valve Replacement   Mechanical valves can pose problems on imaging, but Ronald Wharton, MD, shows you how to see through the shadows.
  • ECG Challenge: Tired and Out of Control An older woman presents with hypertension and lightheadedness. What does her ECG show?
  • How to Know When It's Autoimmune Epilepsy A conversation between Drs Andrew Wilner and Batool Kirmani on the red flags your patient may have this difficult-to-diagnosis condition.
  • Beyond Statins: PCSK9 Inhibitors, Ezetimibe, and Diet   Experts from the Mayo Clinic discuss the spectrum of nonstatin therapies and when they consider using ezetimibe and PCSK9 inhibitors in their patients at high cardiovascular risk.
  • New Lipid Guidelines: A Primary Care Perspective   What are the key takeaways from new AHA/ACC cholesterol guidelines for primary care?
  • Viral Hepatitis: Five Highlights From the Liver Meeting Dr William Balistreri reports on the most important viral hepatitis news from this year's Liver Meeting.
  • PIONEER: A Role for ARNI in Stabilized Acute HF?   Sacubitril/valsartan (Entresto) was studied in patients with acute decompensated heart failure in the PIONEER HF Trial. Dr Piña gets the details from lead investigator Eric Velazquez.
  • The New Seizure Terminology No more 'grand mal' or even 'partial complex seizures.' Find out which terms are outdated and which are newer and more accurate.
  • ACC/AHA 2018 Cholesterol Guideline: The New and the Old   Drs Michael Blaha and Salim Virani review key takeaways from the 2018 ACC/AHA updated cholesterol guideline, noting that much is new in management of patients with elevated lipids.
  • CV Risk Assessment: A Process, Not a Calculation   Tips on how to estimate, personalize, and reclassify patient risk in light of the new cholesterol guidelines. Dr Blaha walks through a typical patient case with guideline writer Dr Lloyd-Jones
  • AHA 2018Think You're Immune From Bias? Think Again John Mandrola, MD, is intrigued by two studies at AHA that track the cognitive and financial biases that may influence what physicians do in practice and how they write and read research papers.
  • AHA 2018What's Needed After AHA 2018? ACTION A sparsely attended session on social determinants of health sounded very familiar to Melissa Walton-Shirley, MD. So if we know what to do to improve CV health, why haven’t we done it yet?
  • CV Risk: Can Prescription Omega-3 REDUCE-IT?   Low-dose omega-3 flopped for CV risk reduction. Melissa Walton-Shirley, MD, dissects the REDUCE-IT trial from AHA, which used high-dose prescription EPA, with principal investigator, Deepak Bhatt, MD.
  • Infectious Theory of Alzheimer Disease Draws Fresh Interest More and more research supports the theory that Alzheimer disease, at least in some cases, may be caused by an early-life infection.
  • AHA 2018Nothing Fishy: Triglyceride Lowering With High-Dose EPA   How do the findings from the REDUCE-IT trial square with prior data on triglycerides and CVD? Prof Armitage sees a pattern.
  • AHA 2018ENCORE-VT: Noninvasive Ablation of VT Could Disrupt EP A small study suggests that ventricular arrhythmia may be treated without the need for catheters and anesthesia. John Mandrola, MD, is impressed with the findings and the investigators' lack of hyperbole.
  • AHA 2018Glad Your EF Is Better, But Stay on Your Meds While the TRED-HF trial may not be great news for patients with dilated cardiomyopathy and recovered EF, at least it eases this physician's conscience about her reluctance to curtail pharmacotherapy.
  • AHA 2018Lipid Lollapalooza at AHA 2018 The release of the 2018 cholesterol guidelines and a bunch of lipid-oriented trials made it a bountiful day at the American Heart Association meeting for Melissa Walton-Shirley, MD.
https://viagra-on.com

www.steroid-pharm.com

www.steroid-pharm.com